1 completed, 1 suspended. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Suspended 1 |
Follow Corteria Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CRF2 Agonist for the Treatment of Worsening Heart Failure COR-1167, Placebo - Worsening Heart Failure | Phase 2 | Suspended | Corteria Pharmaceuticals | 300 | 2025-08-07 | 2026-07-22 |
| Multiparametric Assessment of Cardiac Congestion in Outpatient Worsening Heart Failure Observational study - Heart Failure, Heart Decompensation | Completed | Corteria Pharmaceuticals | 42 | 2022-09-28 | 2024-02-13 |
Heart Failure (1)
Observation (1)
Armenia (1) · Bosnia and Herzegovina (1) · Czechia (1) · Georgia (1) · Hungary (1) · Poland (1) · Romania (1) · Serbia (1) · Spain (1) · United States (1)
Alexandre Mebazaa, MD (1) · Jeffrey Testani, MD (1)
PMID 19919977, PMID 21536988, PMID 24446411, PMID 24621976, PMID 27207191, PMID 29544928